
Biotechnology Assets SA
MAD:BST

Intrinsic Value
The intrinsic value of one
BST
stock under the Base Case scenario is
0.23
EUR.
Compared to the current market price of 0.39 EUR,
Biotechnology Assets SA
is
Overvalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Biotechnology Assets SA
Loading...
Fundamental Analysis


Revenue & Expenses Breakdown
Biotechnology Assets SA
Balance Sheet Decomposition
Biotechnology Assets SA
Current Assets | 3.7m |
Cash & Short-Term Investments | 261.8k |
Receivables | 3.4m |
Non-Current Assets | 11.1m |
Long-Term Investments | 448.3k |
PP&E | 2.3m |
Intangibles | 5.6m |
Other Non-Current Assets | 2.7m |
Free Cash Flow Analysis
Biotechnology Assets SA
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Biotechnology Assets SA
Revenue
|
2.5m
EUR
|
Cost of Revenue
|
-600.5k
EUR
|
Gross Profit
|
1.9m
EUR
|
Operating Expenses
|
-3.9m
EUR
|
Operating Income
|
-2m
EUR
|
Other Expenses
|
-914.7k
EUR
|
Net Income
|
-2.9m
EUR
|
BST Profitability Score
Profitability Due Diligence
Biotechnology Assets SA's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Score
Biotechnology Assets SA's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
BST Solvency Score
Solvency Due Diligence
Biotechnology Assets SA's solvency score is 33/100. The higher the solvency score, the more solvent the company is.

Score
Biotechnology Assets SA's solvency score is 33/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BST Price Targets Summary
Biotechnology Assets SA
Dividends
Current shareholder yield for BST is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
BST
stock under the Base Case scenario is
0.23
EUR.
Compared to the current market price of 0.39 EUR,
Biotechnology Assets SA
is
Overvalued by 41%.